Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination

Molecular Therapy

Volumn 6, Issue 4, 2002, Pages 519-527

  Siders, William M ^a   Vergillis, Kristin ^a   Johnson, Carrie ^a   Scheule, Ronald K ^b   Kaplan, Johanne M ^b  

^a Genzyme Molecular Oncology   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Cancer; Cationic lipid; Immunostimulation; Immunotherapy; Melanoma

Indexed keywords

CARBAMIC ACID ESTER; CD4 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL ESTER; GL 67; MELANOMA ANTIGEN; PLASMID DNA; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; IMMUNE RESPONSE; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; TUMOR GROWTH;

ANIMALIA;

EID: 0036799658     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0697     Document Type: Article

References (17)

1. Lanuti, M., et al. (2000). Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res. 60: 2955-2963.
2. Rudginsky, S., et al. (2001). Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol. Ther. 4: 347-355, doi10.1006/mthe.2001.0463
3. Whitmore, M., Li, S., and Huang, L. (1999). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6: 1867-1875.
4. Dow, S. W,, et al. (1999). Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163: 1552-1561.
5. Bramson, J. L., Bodner, C. A., and Graham, R. W. (2000). Activation of host antitumoral responses by cationic lipid/DNA complexes. Cancer Gene Ther. 7: 353-359.
6. Freimark, B. D., et al. (1998). Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid:cationic lipid complexes. J. Immunol. 160: 4580-4586.
7. Norman, J., et al. (2000). Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 7: 1425-1430.
8. Mezzacasa, P. I., LeDonne, P., Dummer, R., and Hemmi, S. (2001). Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91 -M3. Melanoma Res. 1: 21-30.
9. Fox, B. A., et al. (1998). Lipofection indirectly increases expression of endogenous major histocompatibility complex class I molecules on tumor cells. Cancer Gene Ther. 5: 307-312.
10. Andrews, J. M., Newbound, G. C., and Lairmore, M. D. (1997). Transcriptional modulation of viral reporter gene constructs following induction of the cellular stress response. Nucleic Acids Res. 25: 1082-1084.
11. Binder, R. J., Han, D. K., and Srivastava, P. K. (2000). CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1: 151-155.
12. Krieg, A. M. (1999). Direct immunologic activities of CpG DNA and implications for gene therapy. J. Gene Med. 1: 56-63.
13. Neujahr, D. C., Reich, C. F., and Pisetsky, D. S. (1999). Immunostimulatory properties of genomic DNA from different bacterial species. Immunobiology 200: 106-119.
14. Gooding, L. R. (1977). Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J. Immunol. 118: 920-927.
15. Lee, E. R., et al. (1996). Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7: 1701-1717.
16. Kaplan, J. M., et al. (1999). Induction of antitumor immunity with dendritic cells transduced with adenovirus vector encoding endogenous tumor-associated antigens. J. Immunol. 163: 699-707.
17. Zhai, Y., et al. (1996). Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J. Immunol. 156: 700-710.